HC Wainwright Comments on Alpine Immune Sciences, Inc.’s Q3 2024 Earnings (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Free Report) – Research analysts at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for shares of Alpine Immune Sciences in a note issued to investors on Tuesday, March 19th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings per share of […]

Leave a Reply

Your email address will not be published.

Previous post Brokerages Set DXC Technology (NYSE:DXC) PT at $23.20
Next post HC Wainwright Reiterates Buy Rating for Valneva (NASDAQ:VALN)